M
Michael S. Rafii
Researcher at University of Southern California
Publications - 95
Citations - 3097
Michael S. Rafii is an academic researcher from University of Southern California. The author has contributed to research in topics: Medicine & Dementia. The author has an hindex of 23, co-authored 72 publications receiving 2256 citations. Previous affiliations of Michael S. Rafii include University of California, San Diego & Icahn School of Medicine at Mount Sinai.
Papers
More filters
Journal ArticleDOI
Recent developments in Alzheimer's disease therapeutics
Michael S. Rafii,Paul S. Aisen +1 more
TL;DR: Primary targets include beta-amyloid, whose presence and accumulation in the brain is thought to contribute to the development of Alzheimer's disease, and tau protein, which, when hyperphosphorylated, results in the self-assembly of tangles of paired helical filaments also believed to be involved in the pathogenesis of Alzheimer't disease.
Journal ArticleDOI
A phase II trial of huperzine A in mild to moderate Alzheimer disease
Michael S. Rafii,S. Walsh,John T. Little,K. Behan,Brigid Reynolds,C. Ward,Shelia Jin,R. G. Thomas,Paul S. Aisen +8 more
TL;DR: This study provides Class III evidence that huperzine A 200 μg BID has no demonstrable cognitive effect in patients with mild to moderate AD.
Journal ArticleDOI
A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease.
Michael S. Rafii,Tiffany L. Baumann,Roy A.E. Bakay,Jeffrey M. Ostrove,Joao Siffert,Adam S. Fleisher,Christopher D. Herzog,David Barba,Mary Pay,David P. Salmon,Yaping Chu,Jeffrey H. Kordower,Kathie M. Bishop,David Keator,Steven G. Potkin,Raymond T. Bartus +15 more
TL;DR: Nerve growth factor is an endogenous neurotrophic‐factor protein with the potential to restore function and to protect degenerating cholinergic neurons in Alzheimer's disease, but safe and effective delivery has proved unsuccessful.
Journal ArticleDOI
Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia: A Randomized Clinical Trial.
Suzanne Craft,Rema Raman,Tiffany W. Chow,Michael S. Rafii,Chung-Kai Sun,Robert A. Rissman,Robert A. Rissman,Michael C. Donohue,James B. Brewer,James B. Brewer,Cecily Jenkins,Kelly Harless,Devon Gessert,Paul S. Aisen +13 more
TL;DR: No cognitive or functional benefits were observed with intranasal insulin treatment over a 12-month period among the primary intention-to-treat cohort and no clinically important adverse events were associated with treatment.
Journal ArticleDOI
Agrin and microvascular damage in Alzheimer's disease.
Tyler M. Berzin,Brian D. Zipser,Michael S. Rafii,V. Kuo-LeBlanc,George D. Yancopoulos,David J. Glass,Justin R. Fallon,Edward G. Stopa,Edward G. Stopa +8 more
TL;DR: Examining the distribution of agrin and laminin within the VBM, and measuring the agrin concentration within hippocampus and prefrontal cortex, suggest that agrin is an important VBM-associated HSPG in the brain and that Agrin levels are altered in association with microvascular damage in AD.